256 related articles for article (PubMed ID: 27424662)
1. Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.
Foti RS; Diaz P; Douguet D
J Enzyme Inhib Med Chem; 2016; 31(sup2):148-161. PubMed ID: 27424662
[TBL] [Abstract][Full Text] [Related]
2. Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.
Foti RS; Isoherranen N; Zelter A; Dickmann LJ; Buttrick BR; Diaz P; Douguet D
J Pharmacol Exp Ther; 2016 May; 357(2):281-92. PubMed ID: 26937021
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the
Stevison F; Hogarth C; Tripathy S; Kent T; Isoherranen N
Drug Metab Dispos; 2017 Jul; 45(7):846-854. PubMed ID: 28446509
[No Abstract] [Full Text] [Related]
4. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract][Full Text] [Related]
6. Functional properties and substrate characterization of human CYP26A1, CYP26B1, and CYP26C1 expressed by recombinant baculovirus in insect cells.
Helvig C; Taimi M; Cameron D; Jones G; Petkovich M
J Pharmacol Toxicol Methods; 2011; 64(3):258-63. PubMed ID: 21906690
[TBL] [Abstract][Full Text] [Related]
7. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid.
Taimi M; Helvig C; Wisniewski J; Ramshaw H; White J; Amad M; Korczak B; Petkovich M
J Biol Chem; 2004 Jan; 279(1):77-85. PubMed ID: 14532297
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases.
Topletz AR; Thatcher JE; Zelter A; Lutz JD; Tay S; Nelson WL; Isoherranen N
Biochem Pharmacol; 2012 Jan; 83(1):149-63. PubMed ID: 22020119
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the roles of peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation.
Tay S; Dickmann L; Dixit V; Isoherranen N
Mol Pharmacol; 2010 Feb; 77(2):218-27. PubMed ID: 19884280
[TBL] [Abstract][Full Text] [Related]
10. Lipopolysaccharide opposes the induction of CYP26A1 and CYP26B1 gene expression by retinoic acid in the rat liver in vivo.
Zolfaghari R; Cifelli CJ; Lieu SO; Chen Q; Li NQ; Ross AC
Am J Physiol Gastrointest Liver Physiol; 2007 Apr; 292(4):G1029-36. PubMed ID: 17185629
[TBL] [Abstract][Full Text] [Related]
11. CRABPs Alter
Yabut KCB; Isoherranen N
Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565751
[TBL] [Abstract][Full Text] [Related]
12. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
Diaz P; Huang W; Keyari CM; Buttrick B; Price L; Guilloteau N; Tripathy S; Sperandio VG; Fronczek FR; Astruc-Diaz F; Isoherranen N
J Med Chem; 2016 Mar; 59(6):2579-95. PubMed ID: 26918322
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
[TBL] [Abstract][Full Text] [Related]
14. Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site architecture and ligand binding.
Gomaa MS; Yee SW; Milbourne CE; Barbera MC; Simons C; Brancale A
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):361-9. PubMed ID: 17059167
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.
Nelson CH; Buttrick BR; Isoherranen N
Curr Top Med Chem; 2013; 13(12):1402-28. PubMed ID: 23688132
[TBL] [Abstract][Full Text] [Related]
16. The involvement of cytochrome p450 (CYP) 26 in the retinoic acid metabolism of human epidermal keratinocytes.
Pavez Loriè E; Li H; Vahlquist A; Törmä H
Biochim Biophys Acta; 2009 Mar; 1791(3):220-8. PubMed ID: 19171200
[TBL] [Abstract][Full Text] [Related]
17. CYP26B1 plays a major role in the regulation of all-trans-retinoic acid metabolism and signaling in human aortic smooth muscle cells.
Ocaya PA; Elmabsout AA; Olofsson PS; Törmä H; Gidlöf AC; Sirsjö A
J Vasc Res; 2011; 48(1):23-30. PubMed ID: 20606468
[TBL] [Abstract][Full Text] [Related]
18. Both all-trans retinoic acid and cytochrome P450 (CYP26) inhibitors affect the expression of vitamin A metabolizing enzymes and retinoid biomarkers in organotypic epidermis.
Pavez Loriè E; Chamcheu JC; Vahlquist A; Törmä H
Arch Dermatol Res; 2009 Aug; 301(7):475-85. PubMed ID: 19294396
[TBL] [Abstract][Full Text] [Related]
19. Expression of the retinoic acid catabolic enzyme CYP26B1 in the human brain to maintain signaling homeostasis.
Stoney PN; Fragoso YD; Saeed RB; Ashton A; Goodman T; Simons C; Gomaa MS; Sementilli A; Sementilli L; Ross AW; Morgan PJ; McCaffery PJ
Brain Struct Funct; 2016 Jul; 221(6):3315-26. PubMed ID: 26374207
[TBL] [Abstract][Full Text] [Related]
20. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation.
McSorley LC; Daly AK
Biochem Pharmacol; 2000 Aug; 60(4):517-26. PubMed ID: 10874126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
